As of 2025-04-23, the Relative Valuation of Exagen Inc (XGN) is (9.50) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.43 USD, the upside of Exagen Inc based on Relative Valuation is -314.4%.
The range of the Relative Valuation is (9.32) - (11.80) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 11.0x - 14.7x | 12.0x |
| Forward P/E multiples | 8.8x - 14.0x | 10.5x |
| Fair Price | (9.32) - (11.80) | (9.50) |
| Upside | -310.4% - -366.5% | -314.4% |
| Date | P/E |
| 2025-04-21 | -5.10 |
| 2025-04-17 | -5.32 |
| 2025-04-16 | -5.29 |
| 2025-04-15 | -5.22 |
| 2025-04-14 | -5.45 |
| 2025-04-11 | -5.04 |
| 2025-04-10 | -5.01 |
| 2025-04-09 | -5.21 |
| 2025-04-08 | -4.74 |
| 2025-04-07 | -4.83 |
| 2025-04-04 | -4.77 |
| 2025-04-03 | -5.06 |
| 2025-04-02 | -5.25 |
| 2025-04-01 | -4.65 |
| 2025-03-31 | -4.25 |
| 2025-03-28 | -4.55 |
| 2025-03-27 | -5.02 |
| 2025-03-26 | -5.03 |
| 2025-03-25 | -4.57 |
| 2025-03-24 | -4.80 |
| 2025-03-21 | -4.59 |
| 2025-03-20 | -4.37 |
| 2025-03-19 | -4.44 |
| 2025-03-18 | -4.29 |
| 2025-03-17 | -4.29 |
| 2025-03-14 | -4.22 |
| 2025-03-13 | -3.97 |
| 2025-03-12 | -3.94 |
| 2025-03-11 | -3.99 |
| 2025-03-10 | -3.38 |
| 2025-03-07 | -3.83 |
| 2025-03-06 | -3.71 |
| 2025-03-05 | -3.78 |
| 2025-03-04 | -3.56 |
| 2025-03-03 | -3.62 |
| 2025-02-28 | -4.10 |
| 2025-02-27 | -4.20 |
| 2025-02-26 | -4.17 |
| 2025-02-25 | -4.09 |
| 2025-02-24 | -4.26 |
| 2025-02-21 | -4.24 |
| 2025-02-20 | -4.48 |
| 2025-02-19 | -4.55 |
| 2025-02-18 | -4.46 |
| 2025-02-14 | -5.01 |
| 2025-02-13 | -5.06 |
| 2025-02-12 | -5.12 |
| 2025-02-11 | -5.67 |
| 2025-02-10 | -5.68 |
| 2025-02-07 | -6.11 |